151 related articles for article (PubMed ID: 11019861)
1. Four structural risk factors identify most fibril-forming kappa light chains.
Stevens FJ
Amyloid; 2000 Sep; 7(3):200-11. PubMed ID: 11019861
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity in primary structure, post-translational modifications, and germline gene usage of nine full-length amyloidogenic kappa1 immunoglobulin light chains.
Connors LH; Jiang Y; Budnik M; Théberge R; Prokaeva T; Bodi KL; Seldin DC; Costello CE; Skinner M
Biochemistry; 2007 Dec; 46(49):14259-71. PubMed ID: 18004879
[TBL] [Abstract][Full Text] [Related]
3. Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oligomers and fibrils.
Ren R; Hong Z; Gong H; Laporte K; Skinner M; Seldin DC; Costello CE; Connors LH; Trinkaus-Randall V
J Biol Chem; 2010 Nov; 285(48):37672-82. PubMed ID: 20870723
[TBL] [Abstract][Full Text] [Related]
4. Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycans.
Blancas-Mejía LM; Hammernik J; Marin-Argany M; Ramirez-Alvarado M
J Biol Chem; 2015 Feb; 290(8):4953-4965. PubMed ID: 25538238
[TBL] [Abstract][Full Text] [Related]
5. A glycosylated Bence Jones protein and its autologous amyloid light chain containing potentially amyloidogenic residues.
Foss GS; Nilsen R; Cornwell GC; Husby G; Sletten K
Scand J Immunol; 1998 Apr; 47(4):348-54. PubMed ID: 9600316
[TBL] [Abstract][Full Text] [Related]
6. Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains.
Raffen R; Dieckman LJ; Szpunar M; Wunschl C; Pokkuluri PR; Dave P; Wilkins Stevens P; Cai X; Schiffer M; Stevens FJ
Protein Sci; 1999 Mar; 8(3):509-17. PubMed ID: 10091653
[TBL] [Abstract][Full Text] [Related]
7. An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis.
Nevone A; Girelli M; Mangiacavalli S; Paiva B; Milani P; Cascino P; Piscitelli M; Speranzini V; Cartia CS; Benvenuti P; Goicoechea I; Fazio F; Basset M; Foli A; Nanci M; Mazzini G; Caminito S; Sesta MA; Casarini S; Rognoni P; Lavatelli F; Petrucci MT; Olimpieri PP; Ricagno S; Arcaini L; Merlini G; Palladini G; Nuvolone M
Leukemia; 2022 Aug; 36(8):2076-2085. PubMed ID: 35610346
[TBL] [Abstract][Full Text] [Related]
8. Identification and location of a cysteinyl posttranslational modification in an amyloidogenic kappa1 light chain protein by electrospray ionization and matrix-assisted laser desorption/ionization mass spectrometry.
Lim A; Wally J; Walsh MT; Skinner M; Costello CE
Anal Biochem; 2001 Aug; 295(1):45-56. PubMed ID: 11476544
[TBL] [Abstract][Full Text] [Related]
9. Towards understanding the structure-function relationship of human amyloid disease.
Dealwis C; Wall J
Curr Drug Targets; 2004 Feb; 5(2):159-71. PubMed ID: 15011949
[TBL] [Abstract][Full Text] [Related]
10. Altered dimer interface decreases stability in an amyloidogenic protein.
Baden EM; Owen BA; Peterson FC; Volkman BF; Ramirez-Alvarado M; Thompson JR
J Biol Chem; 2008 Jun; 283(23):15853-60. PubMed ID: 18400753
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin kappa light chain and its amyloidogenic mutants: a molecular dynamics study.
Nowak M
Proteins; 2004 Apr; 55(1):11-21. PubMed ID: 14997536
[TBL] [Abstract][Full Text] [Related]
12. Structural analysis of the amyloidogenic kappa Bence Jones protein (FUR).
Odani S; Komori Y; Gejyo F
Amyloid; 1999 Jun; 6(2):77-88. PubMed ID: 10439113
[TBL] [Abstract][Full Text] [Related]
13. Structural insights into the role of mutations in amyloidogenesis.
Baden EM; Randles EG; Aboagye AK; Thompson JR; Ramirez-Alvarado M
J Biol Chem; 2008 Nov; 283(45):30950-6. PubMed ID: 18768467
[TBL] [Abstract][Full Text] [Related]
14. Tertiary structure of an amyloid immunoglobulin light chain protein: a proposed model for amyloid fibril formation.
Schormann N; Murrell JR; Liepnieks JJ; Benson MD
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9490-4. PubMed ID: 7568160
[TBL] [Abstract][Full Text] [Related]
15. Light chain-associated amyloid deposits comprised of a novel kappa constant domain.
Solomon A; Weiss DT; Murphy CL; Hrncic R; Wall JS; Schell M
Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9547-51. PubMed ID: 9689117
[TBL] [Abstract][Full Text] [Related]
16. Extended analysis of AL-amyloid protein from abdominal wall subcutaneous fat biopsy: kappa IV immunoglobulin light chain.
Olsen KE; Sletten K; Westermark P
Biochem Biophys Res Commun; 1998 Apr; 245(3):713-6. PubMed ID: 9588180
[TBL] [Abstract][Full Text] [Related]
17. ALkappa(I) (UNK) - primary structure of an AL-amyloid protein presenting an organ-limited subcutaneous nodular amyloid syndrome of long duration. Case report and review.
Wiegel NM; Mentele R; Kellermann J; Meyer L; Riess H; Linke RP
Amyloid; 2010 Mar; 17(1):10-23. PubMed ID: 20146644
[TBL] [Abstract][Full Text] [Related]
18. Localized laryngeal amyloidosis: partial characterization of an amyloid fibril protein AL.
Westermark P; Sletten K; Pitkänen P; Natvig JB; Lindholm CE
Mol Immunol; 1982 Mar; 19(3):447-50. PubMed ID: 6808355
[TBL] [Abstract][Full Text] [Related]
19. Fragments of the constant region of immunoglobulin light chains are constituents of AL-amyloid proteins.
Olsen KE; Sletten K; Westermark P
Biochem Biophys Res Commun; 1998 Oct; 251(2):642-7. PubMed ID: 9792827
[TBL] [Abstract][Full Text] [Related]
20. Light chain amyloidosis - current findings and future prospects.
Baden EM; Sikkink LA; Ramirez-Alvarado M
Curr Protein Pept Sci; 2009 Oct; 10(5):500-508. PubMed ID: 19538145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
